Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

The Oncology Institute Inc WT (TOIIW)

The Oncology Institute Inc WT (TOIIW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 324,239 K
  • Annual Income, $ -83,068 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0100 +20.00%
on 11/05/24
0.0237 -49.37%
on 10/24/24
-0.0080 (-40.00%)
since 10/22/24
3-Month
0.0100 +20.00%
on 11/05/24
0.0380 -68.42%
on 09/30/24
-0.0079 (-39.70%)
since 08/21/24
52-Week
0.0100 +20.00%
on 11/05/24
0.3699 -96.76%
on 02/09/24
-0.1681 (-93.34%)
since 11/22/23

Most Recent Stories

More News
The Oncology Institute Reports Third Quarter 2024 Financial Results

TOIIW : 0.0120 (-1.64%)
TOI : 0.1540 (-0.65%)
The Oncology Institute Announces Certification to Administer Pluvicto Therapy in California

TOIIW : 0.0120 (-1.64%)
TOI : 0.1540 (-0.65%)
The Oncology Institute Announces Third Quarter 2024 Earnings Release Date and Conference Call

TOIIW : 0.0120 (-1.64%)
TOI : 0.1540 (-0.65%)
The Oncology Institute Joins Lantern’s Cancer Care Network of Excellence

TOIIW : 0.0120 (-1.64%)
TOI : 0.1540 (-0.65%)
The American Journal of Managed Care® and The Oncology Institute to Co-Host Symposium for Value-Based Cancer Care

TOIIW : 0.0120 (-1.64%)
TOI : 0.1540 (-0.65%)
The Oncology Institute Reports Second Quarter 2022 Financial Results and Reaffirms Full Year 2022 Guidance

CERRITOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups...

TOIIW : 0.0120 (-1.64%)
TOI : 0.1540 (-0.65%)
The Oncology Institute announces $110 million strategic investment by Deerfield Management to accelerate its expansion into new markets

Investment to accelerate Company’s expansion into new markets, bringing high-quality, value-based care to more patients...

TOIIW : 0.0120 (-1.64%)
TOI : 0.1540 (-0.65%)
The Oncology Institute Continues Southern California Expansion

Orange County-based practice of Dr. Ranjan Sapra to combine with TOI....

TOIIW : 0.0120 (-1.64%)
TOI : 0.1540 (-0.65%)
The Oncology Institute set to join the Russell 2000® and Russell 3000® Indexes

CERRITOS, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the...

TOIIW : 0.0120 (-1.64%)
TOI : 0.1540 (-0.65%)
The Oncology Institute Announces Opening of Austin’s Newest Innovative Cancer Clinics

The company is making world-class, community-based cancer care more accessible to Texas residents...

TOIIW : 0.0120 (-1.64%)
TOI : 0.1540 (-0.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar